financetom
Business
financetom
/
Business
/
Exxon Mobil signals weaker oil and gas prices to hit first-quarter profit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exxon Mobil signals weaker oil and gas prices to hit first-quarter profit
Apr 3, 2024 3:22 PM

HOUSTON, April 3 (Reuters) - Exxon Mobil ( XOM ) on

Wednesday signaled first-quarter operating results would drop

over the prior quarter on weaker oil, gas prices and a big loss

in fuel derivatives, a securities filing showed.

The drop follows two years of strong oil and fuel prices

that turned the largest U.S. oil company into one of the most

profitable energy companies globally. Last year, it posted a

record profit for a first quarter at $11.4 billion.

The biggest impact in the latest quarter came from weak

natural gas prices and fuel derivatives, which reversed course

after run-ups last year.

Overall, the snapshot shows about $6.65 billion in operating

profit for the quarter, compared to $11.6 billion in the same

quarter a year ago and $7.63 billion in the fourth quarter.

Investors expect the company to post an adjusted per share

profit of $2.21, compared to the year-ago's $2.83, according to

financial firm LSEG's consensus estimate.

Natural gas prices fell to multi-year lows during the

quarter. Overall weaker oil and gas prices alone cut Exxon's

profits by about $600 million compared to the fourth quarter of

2023.

The company also said fuel derivatives undercut gains in

gasoline and diesel margins, costing it about $1.1 billion

compared to the fourth quarter. Refining maintenance costs also

jumped last quarter, the filing showed.

Last year's financial gains led Exxon to pursue all-stock

deals for U.S. shale oil producer Pioneer Natural Resources

and carbon storage firm Denbury. Its shares were up

16.2% during the first quarter and finished at $119.30 on

Wednesday.

The company also claims a preemptive right over Hess Corp's

Guyana assets, the prize in Chevron's $53 billion offer

for Hess. That claim is being considered by an international

arbitration panel.

The company is expected to post full results for the period

on April 26.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CRH Gains Shareholder Approval for Acquisition of Adbri
CRH Gains Shareholder Approval for Acquisition of Adbri
Jun 14, 2024
05:26 AM EDT, 06/14/2024 (MT Newswires) -- CRH (CRH) said Friday that Adbri's independent shareholders have approved a plan through which it will acquire a majority stake in Adbri for 1.1 billion Australian dollars ($727.3 million). The plan received court approval on Friday. The deal has already secured regulatory approval and is expected to close on July 1, 2024. Under...
Ultragenyx Pharmaceutical Prices $350 Million Offering
Ultragenyx Pharmaceutical Prices $350 Million Offering
Jun 14, 2024
05:18 AM EDT, 06/14/2024 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said late Thursday it has priced an underwritten public offering of 7.4 million common shares at $39 per share for expected gross proceeds of about $350 million. The company is offering pre-funded warrants, in lieu of common stock to certain investors, to purchase about 1.5 million shares at...
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years
Jun 14, 2024
05:21 AM EDT, 06/14/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday that results from the phase 2 MagnetisMM-3 study of ELREXFIO in patients with heavily pretreated relapsed or refractory multiple myeloma showed a median overall survival of 24.6 months, with median progression-free survival of 17.2 months. After more than two years of follow-up in the MagnetisMM-3 trial, the...
Avidity Biosciences Prices $400.9 Million Offering of Shares
Avidity Biosciences Prices $400.9 Million Offering of Shares
Jun 14, 2024
05:28 AM EDT, 06/14/2024 (MT Newswires) -- Avidity Biosciences ( RNA ) said late Thursday it priced an offering of almost 10.6 million shares at $38 apiece for expected gross proceeds of $400.9 million. The company granted underwriters a 30-day option to purchase up to about 1.6 million additional shares in the offering. The sale will likely close on or...
Copyright 2023-2026 - www.financetom.com All Rights Reserved